Having routinely achieved capabilities unmet in the current commercial desktop DNA sequencing platform, such as 600 base reads at 95% read yields at per-base accuracies greater than 99.97% supporting homopolymer and simple repeat read lengths of 9 bases, we have decided to focus on commercialization and begin the build of the GnuBIO beta system instruments ahead of schedule, stated Sepehr Kiani, Executive Vice President of product development. Sourcing parts and choosing leading vendors is an essential part of the build process, and we are pleased to announce that GnuBIO www.gnubio.com is a licensee of the Intel® Brand Advantage Program which is designed to help businesses differentiate their intelligent, connected products through co-branding with one of the worlds most recognized brands, Kiani continued.
The GnuBIO system has a completely integrated workflow, inclusive of genomic selection, amplification, sequencing and real time informatics (assembly and variant calling), allowing researchers and clinicians to simply inject genomic DNA, and walk away with data on the target regions in approximately 2 hours. The commercial system is anticipated to sell for $50K USD, and will not require any additional sample preparation systems or informatics clusters. By simplifying the workflow of DNA sequencing, GnuBIO www.gnubio.com is propagating a powerful technology that will have a profound effect on both patient care as well as the overall healthcare system, stated John Boyce, President, CEO, and Co-Founder. The GnuBIO system will bridge DNA sequencing and molecular diagnostics by simplifying a complex process, eliminating the upfront sample preparation process, allowing technicians to simply inject genomic DNA and walk away, Boyce continued. We are extremely pleased with the progress that we have made to date, and are now transitioning the company from the development phase to the commercial phase.
GnuBIO, Inc. (www.gnubio.com) is a private company and a pioneer in the field of scalable DNA sequencing technology for the Diagnostic and Applied Markets. Utilizing its proprietary microfluidic and emulsion technologies, GnuBIO will work within these markets to develop nucleic acid analysis based systems that scale as a function of both patient sample and genomic region. The GnuBIO system has the capability of running numbers of samples that are in line with diagnostic and applied market requirements for a cost that is orders of magnitude lower than with current technology.
The GnuBIO system has a completely integrated workflow, inclusive of genomic selection, amplification, sequencing and real time informatics (assembly and variant calling), allowing researchers and clinicians to simply inject genomic DNA, and walk away with data on the target regions in approximately 2 hours.
Intel is a trademark of Intel Corporation in the U.S. and other countries.
Susie Truong Harborth
Senior Vice President, Business Operations